Anonymous24 days ago
A new analysis of FDA adverse event data published in the British Journal of Ophthalmology reveals that Wegovy, the higher-dose semaglutide weight-loss injection, carries nearly five times greater risk of ischemic optic neuropathy — a sudden, often permanent form of vision loss — compared to its lower-dose sibling Ozempic. The findings add to a growing body of evidence linking GLP-1 receptor agonists to rare but devastating eye conditions, raising urgent questions about dose-dependent safety as roughly 10 million Americans now take these blockbuster drugs.